Bruno Benedetto, Auner Holger W, Gahrton Gösta, Garderet Laurent, Festuccia Moreno, Ladetto Marco, Lemoli Roberto M, Massaia Massimo, Morris Curly, Palumbo Antonio, Schönland Stefan, Boccadoro Mario, Kröger Nicolaus
a Division of Hematology , University of Torino , Torino , Italy ;
b Department of Molecular Biotechnology and Health Sciences , University of Torino , Torino , Italy ;
Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6.
The European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians working in the field gathered to discuss a variety of topics including the results of recent clinical trials, basic research, the concept of minimal residual disease, and immune modulation. As individual presentations revealed, important advances have occurred in our understanding of the pathophysiology of myeloma and the role that SCT, along with other forms of immunotherapy, plays in treating it. Each presentation stimulated discussion and exchange of ideas among the attendants. We decided to summarize and, importantly, to update the meeting proceedings in this review to share stimulating discussions and ideas on potentially novel treatment strategies among clinicians.
欧洲血液与骨髓移植学会慢性恶性肿瘤工作组于2014年9月25日至26日在意大利都灵召开了一次导师指导会议,以讨论干细胞移植(SCT)在多发性骨髓瘤及其他浆细胞疾病治疗中的作用。该领域的科学家和临床医生齐聚一堂,讨论了包括近期临床试验结果、基础研究、微小残留病概念及免疫调节等在内的各种话题。正如各场个人报告所揭示的,我们对骨髓瘤病理生理学的理解以及SCT与其他形式免疫疗法在治疗骨髓瘤中所起的作用都取得了重要进展。每场报告都激发了与会者之间的讨论和思想交流。我们决定在本综述中总结并重要的是更新会议议程,以便在临床医生中分享关于潜在新治疗策略的精彩讨论和观点。